Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (3): 521-529    DOI: 10.31083/j.ejgo.2021.03.2093
Original Research Previous articles | Next articles
Exploration on correlation of high DLX2 expression with poor prognosis and cellular proliferation in epithelial ovarian cancers
Meng-Hui Huang1, , Yun Han1, , Qing-Hua Xi2, Yun-Feng Jin2, Ying-Lei Liu1, Yu-Wen Han1, Hai-Li Kai1, Qian Zhang1, Yan-Li Zheng1, *()
1Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nantong University, NO. 6 North Hai-er-xiang Road, 226001 Nantong, China
2Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, NO. 20 Xi-si Road, 226001 Nantong, China
Download:  PDF(5410KB)  ( 57 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: It has been found that overexpression of distal-less homeobox 2 (DLX2) is closely correlated with multiple cancers. However, the role of DLX2 in the pathogenesis of ovarian cancers is not known. This study was designed to explore the mechanism of action of DLX2 on cellular proliferation and apoptosis in epithelial ovarian cancers (EOCs). Methods: A total of 119 EOC tissue specimens were analyzed immunohistochemically, and the correlation between DLX2 expressional level and clinicopathological characteristics was determined. Moreover, western blot method was used to measure DLX2 protein in EOC specimen of different grades and EOC cell lines and explore its molecular mechanism of action. Kaplan-Meier survival analysis revealed that overexpression of DLX2 was obviously correlated with an adverse clinical outcome in EOCs (P < 0.01*). Results: DLX2 expressional level had an obvious association with histopathological grade, FIGO stage, ascites and ki-67 expressional level in EOC patients and DLX2 exerted a crucial effect in regulating cellular proliferation in EOCs. Knocking down DLX2 using shRNA-DLX2 reduced the proliferation and enhanced the apoptosis in EOC cells. Conclusion: DLX2 might act as a new prognostic indicator and have an important value for molecular targeted therapeutic drugs in EOCs.
Key words:  Epithelial ovarian cancer (EOC)      DLX2      Proliferation     
Submitted:  22 March 2020      Revised:  26 May 2020      Accepted:  17 June 2020      Published:  15 June 2021     
Fund: 
JC2020006/The Science and Technology Projects Fund of Nantong City
MS12018007/The Science and Technology Projects Fund of Nantong City
MS12019004/The Science and Technology Projects Fund of Nantong City
F201836/The Maternal and Child Health Research Projects Fund of Jiangsu Province
*Corresponding Author(s):  Yan-Li Zheng     E-mail:  gaoshan1189@sina.com
About author:  These authors contributed equally.

Cite this article: 

Meng-Hui Huang, Yun Han, Qing-Hua Xi, Yun-Feng Jin, Ying-Lei Liu, Yu-Wen Han, Hai-Li Kai, Qian Zhang, Yan-Li Zheng. Exploration on correlation of high DLX2 expression with poor prognosis and cellular proliferation in epithelial ovarian cancers. European Journal of Gynaecological Oncology, 2021, 42(3): 521-529.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.03.2093     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I3/521

[1] Yu Fu, Rui-Rui Jin, Yi-Lin Li, Hua Luan, Tao Huang, Yuan Zhao, Lin Yang, Fa-Hui Niu, Qing-Mei Sun, Qing Liu, Yong-Xiu Yang. Isocorydine inhibits the proliferation of human endometrial carcinoma HEC-1B cells by downregulating the Ras/MEK/ERK signaling pathway[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 548-553.
[2] Tao Wei, Mei-Hua Gao, Ying Li. Effect of CD59-targeted multi-directional intervention on transmembrane apoptotic signal transduction of cervical cancer HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 713-719.
[3] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[4] Xifang Lv, Amanguli, Ping Yang. The role of sodium hydrosulfide in the proliferation and apoptosis of exogenous SB203580 pre-treated human ovarian cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 622-628.
[5] Yanhua Li, Rui Liu, Jiang Li, Xudong Dong, Jinsong Shen, Shaoyuan Wu. Isoflurane promotes proliferation and invasion of cervical carcinoma cells via downregulation of miR-375 expression[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 368-372.
[6] G. Yu, J. Liu, X. Sui, T. Wang, W. Wang, G. Qu. Upregulation of ATF3 expression inhibit the proliferation of human uterine serous carcinoma in vitro[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 984-987.
[7] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[8] Haiyu Tang, Tianyang Gao, Xin Ren, Jin Wu, Jinqian Zhang, Zhi Zhang, Yan Yan. The effect of RNAi silencing Tspan5 expression on the proliferation and migration of human choriocarcinoma cell line JEG-3[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 595-599.
[9] Ling Wang, Xiao-tong Wu, Bo-wei Wang, Qiang Wang, Li-ying Han. miR-145 regulates proliferation and chemotherapy sensitivity of ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 634-640.
[10] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[11] R. Brightwell, K. Eng, S. Lele. Use of hematologic biomarkers during chemotherapy predicts survival in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 378-381.
[12] H. Liu, J. Zhao, J. Lv. Inhibitory effects of miR-101 overexpression on cervical cancer SiHa cells[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 236-240.
[13] X.Q. Zhang, C.Y. Yang, X.F. Rao, J.P. Xiong. Plumbagin shows anti-cancer activity in human breast cancer cells by the upregulation of p53 and p21 and suppression of G1 cell cycle regulators[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 30-35.
[14] X. Li, J. Yang, X. Wang, X. Li, J. Liang, H. Xing. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 100-108.
[15] S. Ling, M. Ruiqin, Z. Guohong, S. Bing, C. Yanshan. Decreased microRNA-206 and its function in cervical cancer[J]. European Journal of Gynaecological Oncology, 2015, 36(6): 716-721.
No Suggested Reading articles found!